{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-111585","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.609572+00:00","generated_at":"2026-06-09T09:00:08.058681+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Merck Q3 revenue $16.0B (+7%), KEYTRUDA up 17%; cuts FY EPS guidance on $5.5B Daiichi Sankyo charge","bullets":["Q3 total sales $16.0B (+7% YoY); GAAP EPS $1.86, Non-GAAP EPS $2.13 (+15% YoY).","KEYTRUDA sales $6.3B (+17%); GARDASIL/GARDASIL 9 sales $2.6B (+13%).","Full-year 2023 sales guidance raised to $59.7-$60.2B; Non-GAAP EPS guidance lowered to $1.33-$1.38 due to $5.5B upfront charge from Daiichi Sankyo collaboration.","Entered collaboration with Daiichi Sankyo for three clinical-stage ADC candidates; upfront payment $5.5B.","FDA approved KEYTRUDA for perioperative NSCLC; priority review for sotatercept (PDUFA March 26, 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-111585","json":"https://secwatch.observer/filing/0001104659-23-111585.json","markdown":"https://secwatch.observer/filing/0001104659-23-111585.md","text":"https://secwatch.observer/filing/0001104659-23-111585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/0001104659-23-111585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/tm2328962d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T09:00:08.058681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2664b37d0564d19198bb72dff8e7b7ef6fb187d","claim":"Merck & Co., Inc. updated its the third quarter of 2023 guidance (raised).","evidence_excerpt":"Incorporated by reference is a press release issued by Merck & Co., Inc. on October 26, 2023, regarding earnings for the third quarter of 2023, attached as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/0001104659-23-111585-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}